OS Therapies reports statistically significant interim 3-year OS benefit
OS Therapies (OSTX) announced a statistically significant benefit for OST-HER2-treated patients in interim 3-year overall survival analysis from its Phase 2b pulmonary metastatic osteosarcoma trial.
New York, New York and Rockville, Maryland--(. - September 8, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or the "Company") said it has reported a statistically significant benefit for OST-HER2-tre…